T1	p 106 135	dependent diabetes mellitus .
T2	p 287 316	II ) diabetic subjects during
T3	p 1144 1156	experimental
T4	p 1219 1237	Type II diabetes .
T5	p 1335 1362	Type II diabetic patients .
T6	i 14 54	angiotensin-converting enzyme inhibitors
T7	i 150 171	captopril monotherapy
T8	i 227 245	placebo-controlled
T9	i 347 379	run-in/drug ; placebo/wash-out )
T10	i 402 411	Captopril
T11	i 626 640	ACE-inhibition
T12	i 771 776	kinin
T13	i 1206 1215	captopril
T14	i 1238 1252	ACE inhibitors
T15	i 1302 1331	antihypertensive intervention
T16	o 175 204	blood pressure and metabolism
T17	o 439 476	systolic and diastolic blood pressure
T18	o 539 546	effects
T19	o 554 602	run-in postprandial blood glucose concentrations
T20	o 626 640	ACE-inhibition
T21	o 765 791	blood kinin concentrations
T22	o 890 1006	Body mass index , fasting plasma insulin , serum electrolyte pattern , uric acid , white blood count , lipid profile
T23	o 1018 1055	hepatic and renal function parameters